Biogen's Spinraza yields long-term preservation of motor development in SMA

Gearing up to compete with a gene therapy in SMA, Biogen presented long-term data from its antisense therapy Spinraza that could help make the case for continued use of the chronic treatment.

Read the full 325 word article

User Sign In